An NCI-designated Comprehensive Cancer Center

Alexey Danilov Lab

The Danilov lab focuses on early drug development in lymphoid malignancies
The Danilov lab focuses on early drug development in lymphoid malignancies, with a goal of ushering novel therapeutic approaches into clinic. The team follows the "bench to bedside to bench" paradigm, where pre-clinical findings in the laboratory lead to initiation of early phase clinical trials in lymphoma. Subsequently, correlative studies advance understanding of cancer biology and drug pharmacodynamics, spurring progress in the field of molecular therapeutics.
 
The Danilov lab also focuses its attention on drug resistance in lymphoma, with emphasis on key signaling pathways (TNF receptor and NFκB signaling). Using stromal co-cultures, the Danilov lab models the tumor-supportive microenvironment in vitro as well as studies drug resistant tumors in vivo. The lab has a track record investigating the function of the ubiquitin-proteasome system in cancer, and has studied proximal components of the UPS (E1 enzymes) as therapeutic targets in lymphoma. Moreover, the lab recently set out to advance understanding of the effect of targeted therapies on T-cell function, thus hoping to inform progress in immuno-oncology.
 

Principal Investigator

Alexey Danilov, M.D., Ph.D.
Hematologist - Oncologist
Role: Principal Investigator
Research Focus: Lymphoma Malignancies

Principal Investigator

Alexey Danilov, M.D., Ph.D.
Hematologist - Oncologist
Role:Principal Investigator
Research Focus: Lymphoma Malignancies

Lab Members

Research Assistant
Postdoctoral Fellow
Research Assistant

Lab Alumni

  • Scott Best – Graduate student, U Washington
  • Taylor Rowland
  • Daniel Coleman P.h.D. – Staff Scientist, OHSU
  • Adam Kittai MD – Assistant Professor of Medicine, Ohio State University
  • J. Claire Godbersen – Staff Scientist
  • Cody Paiva – Medical Student
  • Leigh Ann Humphries M.D. – OBGYN, UPenn
  • Bhargava Sreekantham
  • Peter Kebbekus M.D. P.h.D. – Oncologist in Duluth, MN
  • Sumner Kilmarx
  • Ahsan Kamal
  • Max Gordon
  • Elana Thieme
  • Fei Xu, M.D.

Lab Publications

Default publication image
Alexey Danilov's Publications
To view a complete list of publications, please click the link below.

Clinical 

  1. A Phase Ib/II study of Syk inhibitor entospletinib (GS-9973) in combination with obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and B-cell malignancies
  2. A Phase I Study of pevonedistat (MLN4924) in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and non-Hodgkin lymphoma
  3. A Phase I Study of PI3Kα,δ Inhibitor Copanlisib in Combination with PD-1 Antagonist Nivolumab in Patients with Transformed Chronic Lymphocytic Leukemia (Richter's Transformation) or Non-Hodgkin Lymphoma
  4. A Phase II study of BTK inhibitor acalabrutinib in CLL and autoimmune hemolytic anemia
  5. A Phase II study of PI3K inhibitor duvelisib in CLL
  6. Effect of comorbidities on treatment outcomes in chronic lymphocytic leukemia

News

February 2020

Lab moves to City of Hope National Medical Center

 
December 2019

Max Gordon wins Abstract Achievement Award at the 61stASH Annual Meeting in Atlanta for his presentation "The CLL Comorbidity Index (CLL-CI): a Novel Comorbidity Score"